Grant: Project Grant
Research Institute of the McGill University Health Centre
$309,825.00
Ticagrelor compared to clopidogrel in acute coronary syndromes - the TC4 comparative effectiveness study
FY 2017-18
Summary
Blood thinners are an important medication to prevent cardiac events including death and are recommended for almost all patients after a heart attack. Usually two blood thinners are given for this purpose. Recently new blood thinners have become available. However as only one comparative study has been performed, it is unclear if these new blood thinners provide better outcomes at an acceptable risk of bleeding. This project seeks to gather new evidence that can contribute to answering that question.
Department
Program
Project Grant
Location
Quebec, Canada
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
369160
Name
Brophy James M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Public, Community & Population Health 2
Projecttitle
Ticagrelor compared to clopidogrel in acute coronary syndromes - the TC4 comparative effectiveness study
Programtype2
Operating Grants
Orgnameinp2
Research Institute of the McGill University Health Centre
Cihramount2
$309,825
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Acute Coronary Syndrome; Antiplatelet Drugs; Bayesian Analysis; Cardiology; Comparative Effectiveness
Abstract
Blood thinners are an important medication to prevent cardiac events including death and are recommended for almost all patients after a heart attack. Usually two blood thinners are given for this purpose. Recently new blood thinners have become available. However as only one comparative study has been performed, it is unclear if these new blood thinners provide better outcomes at an acceptable risk of bleeding. This project seeks to gather new evidence that can contribute to answering that question.
Competitiondate
201709
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Brophy, James M
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $309,825~ $0~
